InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

InterCure Ltd.NASDAQ: INCR

Gross Margin · Q2 FY2025 · quarter ended Jun 2025

Gross margin narrows to 30.9%

Gross margin was 30.9% in Q2 FY2025, down 2.2 pp from a year earlier. On a trailing-twelve-month basis it was 16.7%, down 11.9 pp year over year. Over 3 fiscal years it narrowed by 27.6 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
30.9%+0.0 pp QoQ
Last fiscal yearDec 2025
12.3%-0.4 pp YoY
LTMJun 2025
16.7%-11.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.2 pp——
1 year-0.4 pp——
3 years-27.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
12.3%
Year-over-year change
-0.4pp

Gross Margin vs competitors

How INCR compares with its peers on the latest reported figures

  • INCR's LTM Jun 2025 gross margin of 16.7% is the lowest of the 6 companies compared; the peer median is 60.3%.
  • Its year-over-year change of -11.9 pp is the 5th highest of 6, against a peer median of +5.4 pp.
  • Over three fiscal years its change of -27.6 pp compares with a peer median of +3.0 pp.
INCR Competitors Peer median
Gross Margin for INCR and competitors
Company Period LTM level YoY 3-year change
CAMPCAMP4 Therapeutics CorporationLTM Mar 202676.2% +30.8 pp—
FBIOFortress Biotech, Inc.LTM Mar 202664.5% +3.3 pp+7.6 pp
HYFTMindWalk Holdings Corp.LTM Jan 202660.3% +10.9 pp-1.5 pp
AMWLAmerican Well CorporationLTM Mar 202649.7% +5.4 pp+11.2 pp
ASRTAssertio Holdings, Inc.LTM Mar 202644.3% -17.8 pp-43.1 pp
INCRInterCure Ltd.LTM Jun 202516.7% -11.9 pp-27.6 pp
CRDLCardiol Therapeutics Inc.FY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding INCR) 60.3%+5.4 pp+3.0 pp

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.68M388.68M355.55M238.85M270.2M
Cost of Revenue128.55M233.6M250.46M208.61M237.02M
Gross Profit91.13M155.08M105.1M30.23M33.18M
Gross Margin41.5%39.9%29.6%12.7%12.3%
Research & Development1.24M632K388K414K390K
Selling, General & Admin53.46M97.32M86.24M84.63M80.41M
Operating Expenses62.95M104.46M146.66M97.44M26.45M
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
EBITDA31.17M70.23M(23.9M)(51.31M)(7.29M)
EBITDA Margin14.2%18.1%-6.7%-21.5%-2.7%
Operating Income28.19M50.63M(41.57M)(67.21M)6.73M
Operating Margin12.8%13.0%-11.7%-28.1%2.5%
Interest Income130K844K4.55M2.7M1.56M
Interest Expense5.05M14.69M24.22M20.65M19.66M
Other Income / Expenses(9.45M)(6.79M)(19.72M)(20.12M)(50.84M)
Income Before Tax18.74M43.84M(61.29M)(87.32M)(44.1M)
Pre-Tax Margin8.5%11.3%-17.2%-36.6%-16.3%
Income Tax Expense11.44M93K2.25M(14.53M)(7.32M)
Net Income4.69M44.82M(61.96M)(67.8M)(35.71M)
Net Margin2.1%11.5%-17.4%-28.4%-13.2%
EPS (Basic)0.120.99(1.36)(1.42)(0.63)
EPS (Diluted)0.110.99(1.36)(1.42)(0.63)
Weighted Avg Shares38.49M45.35M45.56M47.77M56.8M
Weighted Avg Shares (Diluted)40.84M45.35M45.57M47.77M56.8M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.